JP2021512635A5 - - Google Patents

Info

Publication number
JP2021512635A5
JP2021512635A5 JP2020542979A JP2020542979A JP2021512635A5 JP 2021512635 A5 JP2021512635 A5 JP 2021512635A5 JP 2020542979 A JP2020542979 A JP 2020542979A JP 2020542979 A JP2020542979 A JP 2020542979A JP 2021512635 A5 JP2021512635 A5 JP 2021512635A5
Authority
JP
Japan
Prior art keywords
car
seq
antigen
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512635A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/027783 external-priority patent/WO2018191748A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/017727 external-priority patent/WO2019157533A1/en
Publication of JP2021512635A publication Critical patent/JP2021512635A/ja
Publication of JP2021512635A5 publication Critical patent/JP2021512635A5/ja
Priority to JP2024193719A priority Critical patent/JP2025032089A/ja
Pending legal-status Critical Current

Links

JP2020542979A 2018-02-12 2019-02-12 腫瘍微小環境を標的とするキメラ抗原受容体 Pending JP2021512635A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193719A JP2025032089A (ja) 2018-02-12 2024-11-05 腫瘍微小環境を標的とするキメラ抗原受容体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862629593P 2018-02-12 2018-02-12
US62/629,593 2018-02-12
US201862658307P 2018-04-16 2018-04-16
PCT/US2018/027783 WO2018191748A1 (en) 2017-04-14 2018-04-16 Chimeric antigen receptor t cells targeting the tumor microenvironment
USPCT/US2018/027783 2018-04-16
US62/658,307 2018-04-16
US201862746895P 2018-10-17 2018-10-17
US62/746,895 2018-10-17
PCT/US2019/017727 WO2019157533A1 (en) 2018-02-12 2019-02-12 Chimeric antigen receptors targeting the tumor microenvironment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193719A Division JP2025032089A (ja) 2018-02-12 2024-11-05 腫瘍微小環境を標的とするキメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2021512635A JP2021512635A (ja) 2021-05-20
JP2021512635A5 true JP2021512635A5 (enExample) 2022-02-22

Family

ID=67548600

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542979A Pending JP2021512635A (ja) 2018-02-12 2019-02-12 腫瘍微小環境を標的とするキメラ抗原受容体
JP2024193719A Pending JP2025032089A (ja) 2018-02-12 2024-11-05 腫瘍微小環境を標的とするキメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193719A Pending JP2025032089A (ja) 2018-02-12 2024-11-05 腫瘍微小環境を標的とするキメラ抗原受容体

Country Status (8)

Country Link
US (1) US20210038646A1 (enExample)
EP (1) EP3752170A4 (enExample)
JP (2) JP2021512635A (enExample)
CN (1) CN111971053A (enExample)
AU (2) AU2019218989B2 (enExample)
CA (1) CA3090546A1 (enExample)
ES (1) ES3068176T3 (enExample)
WO (1) WO2019157533A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132427A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
EP4759318A2 (en) 2017-04-14 2026-06-17 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
CN110832071A (zh) * 2018-09-14 2020-02-21 上海原能细胞医学技术有限公司 表面包含免疫调节剂的细胞及其用途
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US12702708B2 (en) 2019-08-21 2026-08-11 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
CN112480263B (zh) * 2019-09-12 2026-06-05 百欧恩泰(苏州)医药有限公司 一种双特异t细胞激活器活化t细胞的设计及其应用
EP4045663A2 (en) * 2019-10-16 2022-08-24 Umoja Biopharma, Inc. Retroviral vector for univeral receptor therapy
EP4054602A4 (en) 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
EP4061849A4 (en) * 2019-11-21 2024-05-29 Brown University BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH IMPROVED CYTOTOXIC EFFECTS ON TUMOR CELLS
EP4138864A4 (en) * 2020-04-23 2024-07-10 Innovative Cellular Therapeutics Holdings, Ltd. Polyspecific binding molecules and their use in cell therapy
WO2021247525A1 (en) * 2020-06-02 2021-12-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Dual egfr-muc1 chimeric antigen receptor t cells
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230405121A1 (en) * 2020-11-04 2023-12-21 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
JP2023550148A (ja) * 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
EP4267604A1 (en) 2020-12-23 2023-11-01 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN115491358B (zh) * 2021-06-17 2024-09-06 复星凯特生物科技有限公司 一种靶向b7-h3和folr1双打靶点car t的制备及应用
WO2023274386A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向egfr的通用型car-t细胞及其制备方法
CN113969266B (zh) * 2021-10-26 2023-10-13 山东大学齐鲁医院 一种重组溶瘤腺病毒及其应用
EP4426723A4 (en) * 2021-11-04 2025-12-17 Massachusetts Gen Hospital ANTI-MESOTHELIN CAR T-CELL SECRETING TEAMS AND METHODS FOR THEM USE
WO2024148216A2 (en) * 2023-01-05 2024-07-11 Neximmune, Inc. Combination therapy with t cell engager
EP4791764A1 (en) * 2023-10-13 2026-08-19 The General Hospital Corporation Chimeric antigen receptor (car)-t cell engaging antibody molecule (team) formulations and pharmaceutical compositions
WO2025092689A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种表达多特异性抗原结合蛋白的细胞及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US20160017058A1 (en) * 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
JP6665102B2 (ja) * 2014-02-21 2020-03-13 セレクティスＣｅｌｌｅｃｔｉｓ 制御性ｔ細胞をインサイチューで阻害するための方法
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
US20170296623A1 (en) * 2014-12-17 2017-10-19 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
EP3250609A4 (en) * 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US10647778B2 (en) * 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US20190307799A1 (en) * 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
AU2017347686A1 (en) * 2016-10-19 2019-05-02 Cellectis Cell death inducing chimeric antigen receptors
US20200095301A1 (en) * 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
US20190375815A1 (en) * 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP4759318A2 (en) * 2017-04-14 2026-06-17 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
WO2022046935A2 (en) * 2020-08-26 2022-03-03 The Regents Of The University Of California Methods and compositions for treating glioblastoma

Similar Documents

Publication Publication Date Title
US12291561B2 (en) Antigen binding receptors specific for mutated Fc domains
WO2021008610A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
US9200078B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
US20200093861A1 (en) Antigen binding receptor formats
US20230322950A1 (en) Antigen binding receptors
JP2020516276A5 (enExample)
JP2024023228A5 (enExample)
WO2019114235A1 (zh) Pdl1单克隆抗体及其应用
Mertens Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals
CN114502188B (zh) 人工免疫监视嵌合抗原受体及其表达细胞
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
US20250000976A1 (en) Anti-bcma single domain antibodies and therapeutic constructs
Wels et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
Pfeifer Serrahima et al. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies
JP2024012258A (ja) Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
Korn et al. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes
KR102829757B1 (ko) 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
CN114075287B (zh) 人源化bcma抗体和bcma-car-t细胞
US20240158500A1 (en) CD160 Binding Domain
CN115246885B (zh) 一种双特异性抗体及其应用
WO2024037628A1 (zh) 一种双特异性抗体及其应用
JP2024532486A5 (enExample)
CN117586408A (zh) 一种结合tnfr2和b7h3的双特异性抗体
HK40110214A (en) Anti-dll3 chimeric antigen receptors and uses thereof